NeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, greetings, and welcome to the NeuroPace, Inc. Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
Neuropace Inc (NPCE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 3,097,868 | $34,510,250 | 0.18% | ||
| 2. | OrbiMed Advisors Samuel Isaly | 2,614,184 | $29,122,010 | -24% | 0.73% |
| 3. | Soleus Capital Guy Levy | 2,312,957 | $25,766,341 | -12% | 1.71% |
| 4. | Armistice Capital Steven Boyd | 1,152,335 | $12,837,012 | -1% | 0.22% |
| 5. | Driehaus Capital Richard Driehaus | 1,005,358 | $11,199,688 | +26% | 0.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.50 | 62,398 | $93,534.60 | 4,432,948 | 2022-11-22 | Filing | |
| $1.50 | 327,893 | $491,511.61 | 4,370,550 | 2022-11-21 | Filing | |
| $17.00 | 235,000 | $3,995,000.00 | 235,000 | 2021-04-21 | Filing | |
| $17.00 | 2,352 | $39,984.00 | 2,352 | 2021-04-21 | Filing | |
| $17.00 | 588,235 | $9,999,995.00 | 588,235 | 2021-04-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.94 | 34,000 | $541,960.00 | 3,238,199 | 2025-05-14 | Filing | |
| $15.83 | 134,136 | $2,123,372.88 | 3,272,199 | 2025-05-14 | Filing | |
| $13.72 | 78,334 | $1,074,844.31 | 81,993 | 2025-02-21 | Filing | |
| $9.40 | 5,270,845 | $49,545,943.00 | 0 | 2025-02-20 | Filing | |
| $15.00 | 200 | $3,000.00 | 86,762 | 2025-01-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,585,073 | $28,797,713 | 0% | |
| 2. | 2,319,166 | $25,835,510 | 0% | |
| 3. | 1,380,410 | $15,377,767 | 1.99% | |
| 4. | 1,369,276 | $15,253,735 | 0% | |
| 5. | 928,766 | $10,346,453 | 0% |
News See All
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey
NeuroPace, Inc. (NASDAQ:NPCE) is among the best NASDAQ stocks under $50 to buy. Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc.
10 Best NASDAQ Stocks Under $50 to Buy
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception.
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating
On May 28, H.C. Wainwright analyst Yi Chen initiated coverage of NeuroPace, Inc. (NASDAQ:NPCE) with a Buy rating and a price target of $18.
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2025 Earnings Call Transcript
Operator: Greetings and welcome to the NeuroPace First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
NeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Call Transcript
Operator: Greetings and welcome to NeuroPace’s Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
NeuroPace, Inc. (NASDAQ:NPCE) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to NeuroPace's Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to NeuroPace's First Quarter 2024 Conference Call. As a reminder, this call is being recorded.
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript
NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.33.